In many types of cancers, the fragile histidine triad (Fhit) gene is frequently targeted by genomic alterations leading to a decrease or loss of gene and protein expression. Fhit has been described as a tumor suppressor gene because of its ability to induce apoptosis and to inhibit proliferation of tumor cells. Moreover, several studies have shown a correlation between the lack of Fhit expression and tumor aggressiveness, thus suggesting that Fhit could be involved in tumor progression. In this study, we explored the potential role of Fhit during tumor cell invasion. We first showed that a low Fhit expression is associated with in vivo and in vitro invasiveness of tumor cells. Then, we showed that Fhit overexpression in Fhit-negative highly invasive NCI-H1299 cells by transfection of Fhit cDNA and Fhit inhibition in Fhit-positive poorly invasive HBE4-E6/E7 cells by transfection of Fhit small interfering RNA induce, respectively, a decrease and an increase in migratory/invasive capacities. These changes in cell behavior were associated with a reorganization of tight and adherens junction molecules and a regulation of matrix metalloproteinase and vimentin expression. These results show that Fhit controls the invasive phenotype of lung tumor cells by regulating the expression of genes associated with epithelial-mesenchymal transition.
Introduction
The fragile histidine triad (Fhit) gene located at chromosome region 3p14.2 encompassing the common fragile site FRA3B spans about 2 Mb of the human genome. Fhit encodes a 1.1 kb mRNA and a 16.8 kDa protein ubiquitously expressed in epithelial tissues . Fhit behaves in vitro as a typical diadenosine triphosphate (Ap3A) hydrolase, but little is known about its physiological function (Barnes et al., 1996; Pekarsky et al., 2002) . The lack or decrease of Fhit expression, which is a consequence of chromosomal aberrations such as deletions, loss of heterozygosity, promoter methylation or abnormal transcripts, is a common event in most human cancers Pekarsky et al., 2002; Huebner and Croce, 2003) . Several studies have indeed shown that Fhit is inactivated in lung, breast, esophagus, stomach, kidney and cervix carcinomas Ohta et al., 1996; Sozzi et al., 1996; Ishii et al., 2001; Huebner and Croce, 2003) . After its identification in 1996 , Fhit has been rapidly proposed as a tumor suppressor gene (Siprashvili et al., 1997; Ishii et al., 2001) . Fhit gene delivery in various cancer cells has been shown to suppress tumorigenicity in vitro and in vivo in nude mice, by inducing caspase-dependent apoptosis and inhibiting cell proliferation (Siprashvili et al., 1997; Ji et al., 1999; Dumon et al., 2001; Roz et al., 2002; Cavazzoni et al., 2004; Campiglio et al., 2006) . The exact molecular pathway of the tumor suppressive function of Fhit is, however, still unclear. Interestingly, the enzymatic activity of Fhit is not required but the binding to its substrate Ap3A seems to be necessary (Siprashvili et al., 1997; Pace et al., 1998; Trapasso et al., 2003; Campiglio et al., 2006) . Moreover, the reduced expression of Fhit has been correlated with poor differentiation, histological grade, positive node status, distant metastases and worse prognosis in different types of cancers such as tongue, gastric, colon, cervical, breast and lung carcinomas (Huebner and Croce, 2003; Nakata et al., 2006) . These data showing that Fhit inactivation is associated with tumor aggressiveness thus suggest that Fhit could also have an involvement during tumor cell invasion.
The acquisition of invasive properties by tumor cells requires the loss of typical epithelial features (in particular, the decrease of cell cohesion and the loss of cell polarity) and the gain of mesenchymal characteristics (in particular, capacities to degrade the extracellular matrix (ECM) and to migrate), a phenomenon referred to as epithelial-mesenchymal transition (EMT) (Lee et al., 2006; Gavert and Ben Ze'ev, 2008) . Among the mechanisms largely associated with this process is the disruption of intercellular adhesion, a consequence of the reorganization of E-cadherin/b-catenin complexes of adherens junctions (Van Aken et al., 2001; Lee et al., 2006) . The loss of the E-cadherin-mediated cell adhesion is correlated with cell invasion and the re-expression of E-cadherin in highly invasive tumor cells reduces their invasive potential (Van Aken et al., 2001) . Besides its structural role in adherens junction assembly, Ecadherin is also able to sequester to the cell membrane several co-transcriptional factors that can themselves modulate the expression of invasion-associated genes. In particular, its cytoplasmic binding partner b-catenin, once released from cell-cell contacts, accumulates in the cytoplasm and can then translocate to the nucleus, where it forms a complex with T-cell factor (TCF)/ lymphoid enhancer factor (LEF) family members (Gavert and Ben Ze'ev, 2007; Polette et al., 2007) . Even though less documented, the disorganization of occludin/zonula occludens (ZO)-1 tight junction complexes has also been shown to be a hallmark of a migratory/ invasive phenotype in vivo and in vitro (Tobioka et al., 2004; Polette et al., 2005 Polette et al., , 2007 Lee et al., 2006) . Furthermore, similar to b-catenin, ZO-1 can also shuttle between the plasma membrane and the cytosol or the nucleus and intervene in signaling events promoting tumor cell invasion (Reichert et al., 2000; Polette et al., 2005 Polette et al., , 2007 . Besides the loss of cell-cell contacts, tumor invasion is also characterized by the production of matrix metalloproteinases (MMPs) by tumor cells themselves (Polette et al., 2004; Lee et al., 2006) . MMPs constitute a family of secreted and cell surface enzymes that are able to degrade almost all ECM components and that have been shown to be overexpressed in numerous cancers (Chang and Werb, 2001; Polette et al., 2004) . Because of their selective ability to degrade type-IV collagen, which is a major component of the basement membrane, MMP-2 and -9 have been shown to be involved in tumor invasion in vitro and in vivo (Polette et al., 2004) . Membrane-type 1-MMP (MT1-MMP) also has a major involvement in the tumor invasion process not only through its degradative activities against structural ECM components, cell adhesion molecules and some cytokines but also through its function as the physiological activator of MMP-2 (Seiki, 2003) . Moreover, the de novo expression of vimentin by tumor epithelial cells is an event also frequently linked to EMT-associated tumor cell invasion . Vimentin is a type III intermediate filament protein expressed in cells of mesenchymal origin in adult differentiated tissues. Vimentin has also been associated with and is functionally implicated in epithelial cell migration and invasion (Hendrix et al., 1997; Gilles et al., 1999) . Finally, several signaling pathways, such as transforming growth factor-b, nuclear factor-kB, Wnt and RTKs, have been described as EMT inducers because of their ability to activate transcription factors of the Snail, Twist and ZEB1 families (Gavert and Ben Ze'ev, 2008) .
In this study, we investigated the potential role of Fhit during tumor cell invasion and particularly its capacities to regulate the invasive phenotype of tumor cells. Accordingly, we analysed the consequences of Fhit expression modulation in two lung cancer cell lines with different invasive capacities. We observed that Fhit controls cell migration and invasion by regulating EMT key events such as cell-cell adhesion and MMP (MMP-2, MMP-9, MT1-MMP) and vimentin expression.
Results
Loss of Fhit expression is associated with tumor invasion in vivo and in vitro Expression of Fhit mRNA was detected by RT-PCR analysis in a series of non-small cell lung cancer (NSCLC). We found that Fhit was expressed significantly less in lung carcinomas (median: 1.30, min-max: 0.00-3.10) than in normal tissues (median: 3.05, minmax: 0.86-9.80) (Po0.001) (Figure 1a) . In squamouscell carcinomas, we also observed that Fhit expression was significantly reduced in tumors with lymph node involvement (N1 and N2 status) (median: 1.24, minmax: 0.33-2.56) compared to tumors without lymph node involvement (N0 status) (median: 2.20, min-max: 1.30-3.10) (Po0.05) (Figure 1b) . According to the tumor-node-metastasis (TNM) classification, the Fhit mRNA level was also lower in stage II/III squamous-cell carcinomas (median: 1.27, min-max: 0.33-2.56) than in stage I tumors (median: 2.25, min-max: 1.54-3.10) (Po0.05) (Figure 1c ). In addition, patients with a high level of Fhit mRNA tended to survive longer than patients with a weak level (data not shown). Furthermore, in squamous-cell carcinomas, absence of Fhit expression in tumor clusters was consistently observed at the invading front and in tumor cells infiltrating the stroma as shown by immunohistochemistry (Figure 1d) .
To examine the relationship between Fhit expression and in vitro invasive capacities, we compared the level of Fhit analysed by western blotting (Figure 2a ) in various lung and breast carcinoma cell lines checked for their invasive capacities in a modified Boyden chamber assay (Figure 2b ). We found that Fhit was not expressed by the most invasive cell lines (Hs578T, BEAS-2B, BZR, BZR-T33 and NCI-H1299 cells). At first, we observed that Fhit overexpression in NCI-H1299 and Fhit inhibition in HBE4-E6/E7 induced morphological modifications (Figure 3a ). NCI-H1299-Fhit cells showed a more cohesive and epithelioid phenotype than NCI-H1299-mock cells. Conversely, HBE4-E6/E7 transfected with Fhit siRNA were less cohesive and showed lamellipodium-type extensions characteristic of a migratory phenotype compared with HBE4-E6/E7 transfected with the corresponding scrambled siRNA. In addition, we showed by immunocytochemistry that the modulation of Fhit expression influenced the subcellular localization of molecules implicated in tight and adherens junctions ( Figure 3b ). We observed a higher expression of occludin, ZO-1 and b-catenin at the cell membrane in NCI-H1299-Fhit cells compared with NCI-H1299-mock cells, essentially showing a cytoplasmic expression of these adhesion molecules. E-cadherin was not expressed by NCI-H1299 cells and no change was detected when Fhit expression was induced. In contrast, occludin, ZO-1, E-cadherin and b-catenin were delocalized from the cell membrane towards the cytoplasm and/or the nucleus of FhitsiRNA HBE4-E6/E7 transfected cells compared with control cells. As shown by the western blot analysis, total level of the cell junctional proteins were found unchanged with the exception of b-catenin, which was up-regulated in NCI-H1299-Fhit cells (Figure 3c ).
Fhit regulates migration and invasion of lung tumor cells
As the modification of Fhit expression affected cell morphology and cell-cell adhesion, the effect of induction and repression of Fhit expression was tested on the cell behavior in a two-dimensional (2D) and a three-dimensional (3D) migration assay. In the 2D migration assay, trajectories of NCI-H1299-Fhit cells were shorter and migration speed was significantly reduced compared with mock cells (5.24 ± 0.84 and 11.73 ± 0.64 mm/h, respectively) (Po0.05) (Figure 4a ). Trajectories of HBE4-E6/E7 transfected with Fhit siRNA were on the contrary longer and their migration speed was significantly increased compared with control cells (19.30±2.71 and 15.19±0.97 mm/h, respectively) (Po0.05) (Figure 4a ). In the 3D migration assay, as compared with their corresponding control, the induction of Fhit in NCI-H1299 cells and the inhibition of Fhit in HBE4-E6/E7 cells resulted in a lower (4.47 ± 0.37 versus 6.60 ± 0.32 mm/h) (Po0.05) and a 
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A Joannes et al higher migration speed (7.62 ± 2.53 versus 5.47 ± 2.12 mm/h) (Po0.05), respectively ( Figure 4b ). The invasive capacities of different transfected cells were also tested in a modified Boyden chamber assay. The NCI-H1299-Fhit transfectants were less invasive than the mock transfectants (1056±213 versus 3524 ± 1025 invading cells) (Po0.05) (Figure 5a ), whereas the Fhit-siRNA HBE4-E6/E7 transfectants were more invasive than the scrambled siRNA HBE4-E6/E7 transfectants (1585 ± 148 versus 508 ± 266 invading cells) (Po0.05) (Figure 5b ). Involvement of Fhit in cell invasion regulation was also observed in other lung and mammary cell lines by using a modified Boyden chamber assay (Supplementary Figure) . We also showed that incubation with the synthetic MMP inhibitor GM6001 induced a dose-dependent decrease in the invasive capacities of HBE4-E6/E7 transfected with Fhit siRNA (25 mM GM6001: 559 ± 226 invading cells, 50 mM GM6001: 198±102 invading cells and 100 mM GM6001: 98±94 invading cells) (Po0.05), thus demonstrating that this process was MMP-dependent ( Figure 5b ). 
A Joannes et al (7.55 ± 3.77-fold) (Po0.05) mRNA than their respective controls (Figure 6a ). Zymography analysis allowed us to detect a downregulation of both pro-and active forms of MMP-2 (0.26 ± 0.08-fold) (Po0.05) and MMP-9 (0.36 ± 0.09-fold) (Po0.05) proteins in NCI-H1299 cells after induction of Fhit expression (Figure 6b ). On the contrary, both the pro-and active forms of MMP-2 (2.3 ± 1.4-fold) (Po0.05) and MMP-9 (7.3±5.8-fold) (Po0.01) enzymes were upregulated in Fhit-siRNA HBE4-E6/E7 transfectants (Figure 6b ). MT1-MMP was also found to be upregulated at the mRNA (2.62 ± 1.05-fold) (Po0.05) and protein level (2.67±1.87-fold) (Po0.05) after Fhit inhibition in HBE4-E6/E7 cells as shown by RT-PCR (Figure 6a ) and western blot (Figure 6c) analyses, respectively. Furthermore, the quantitative determination of active MT1-MMP revealed a 1.8 ± 0.09-fold increase of MT1-MMP activity in Fhit-siRNA HBE4-E6/E7 transfectants compared with control transfectants (Po0.05) (Figure 6d ). MT1-MMP was not expressed by NCI-H1299 cells (data not shown). We also searched for a potential regulation of the type III intermediate filament vimentin, known to be implicated in cell migration and EMT process. Whereas no regulation of vimentin was observed in NCI-H1299-Fhit transfectants (data not shown), a significant increase of vimentin was shown in Fhit-siRNA HBE4-E6/E7 transfectants both at the mRNA (3.48±0.78-fold) (Po0.05) and at the protein level (2.15 ± 0.59-fold) (Po0.01), as shown by RT-PCR (Figure 6a ) and western blotting (Figure 6c ), respectively.
Discussion
In this study, we show that Fhit controls the invasive phenotype of lung tumor cells. We indeed showed that (a) a low Fhit expression is correlated with tumor invasion in vivo and in vitro, (b) Fhit regulates cell-cell adhesion, (c) Fhit regulates cell migration and invasion, and (d) Fhit regulates MMP and vimentin expression.
We first found that Fhit expression is reduced in human lung carcinoma samples compared with normal lung tissue. This may be attributed to the role of Fhit as a tumor suppressor gene (Pekarsky et al., 2002) . Moreover, its downregulation is correlated with tumor aggressiveness according to the lymph node status and the TNM stage of squamous-cell carcinomas. We also observed that Fhit expression is lost at the invading front of tumor clusters of lung carcinomas. Even though Fhit inactivation has been shown to be frequently detected in preinvasive bronchial lesions (Sozzi et al., 1998; Pekarsky et al., 2002) , these data, along with previous studies showing a link with poor differentiation, lymph node metastasis and poor survival (Pylkkanen et al., 2002; Maruyama et al., 2004; Nakata et al., 2006) , clearly suggest its involvement in later stages of lung tumor progression. This is in agreement with our in vitro data showing a lack of Fhit expression in highly invasive lung and mammary tumor cell lines. Taken together, these in vivo and in vitro results suggest that Fhit inactivation, in addition to its role in tumorigenesis, is implicated in tumor invasion. In the same way, some genes such as E-cadherin also have dual functions in tumor progression as a tumor suppressor and a tumor invasion regulator (Van Aken et al., 2001) . Accordingly, we showed that overexpression of Fhit in a highly invasive NCI-H1299 lung cell line and inhibition of Fhit expression in a poorly invasive HBE4-E6/E7 lung cell line, respectively, induce a decrease and an increase in their migratory and invasive capacities. Furthermore, the cell invasion induced by Fhit inhibition was MMP-dependent. Concomitantly with these modifications of cell behavior, we also observed changes in subcellular localization of tight and adherens junction molecules and a regulation of MMP and vimentin expression. Indeed, NCI-H1299-Fhit transfectants express more occludin, ZO-1 and b-catenin at the cell membrane and less MMP-2 and -9 than the control cells. On the contrary, a loss of occludin, ZO-1, Ecadherin and b-catenin at cell-cell contacts and an upregulation of MMP-2, MMP-9 as well as MT1-MMP and vimentin expression were seen in Fhit-siRNAtransfected HBE4-E6/E7 cells. All these molecules 
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A Joannes et al demonstrated here as regulated by Fhit are known to have key functions in tumor invasion associated with EMT (Polette et al., 2004 (Polette et al., , 2007 Lee et al., 2006; Ben Ze'ev, 2007, 2008) . Even though the mechanisms by which Fhit could regulate EMT in these lung tumor cells remain largely unknown, its ability to reorganize cell-cell adhesion complexes could directly contribute to the modulation of EMT target molecules such as MMPs and vimentin. Interestingly, the reexpression of E-cadherin has been described to repress MMP expression in invasive cancer cells, likely through inhibition of the b-catenin TCF/ LEF signaling pathway (Luo et al., 1999; NawrockiRaby et al., 2003) . Indeed, MT1-MMP has been proven to be a target of the b-catenin/TCF complex as well as MMP-7 and MMP-26 (Brabletz et al., 1999; Crawford et al., 1999; Marchenko et al., 2002; Takahashi et al., 2002) . Moreover, MMP-1, MMP-3 and MMP-9 constitute potential targets of b-catenin/TCF, because their promoters contain TCF-binding sites. ZO-1 regulates MT1-MMP expression in human breast cancer cells and the activation of the MT1-MMP promoter by ZO-1 is associated with the activation of the b-catenin TCF/ LEF signaling pathway . Finally, it has been shown that the vimentin promoter is also a target of the b-catenin/TCF pathway . Therefore, the mechanism by which Fhit suppresses tumor invasion in these cells may involve the b-catenin TCF/LEF signaling pathway. In accordance with this hypothesis, Weiske et al. (2007) have shown that Fhit is a repressor of b-catenin transcriptional activity. Fhit is indeed able to associate with the LEF1/ 
A Joannes et al TCF/b-catenin complex by directly binding to b-catenin and to repress promoter activation of target genes such as cyclin D1, axin 2, survivin and MT1-MMP (Weiske et al., 2007) . However, we described here a regulation of MMP-2 expression by Fhit. To our knowledge, the MMP-2 promoter does not contain any TCF-binding site. All these data further suggest that Fhit may engage another or several signaling pathways to regulate the invasive phenotype of these tumor cells. In particular, Fhit has also been shown to downregulate NF-kB as well as PI3K-Akt-survivin and Ras/Rho GTPase signaling pathways and to be a target of the protein kinase Src (Pekarsky et al., 2004; Nakagawa and Akao, 2006; Semba et al., 2006; Jayachandran et al., 2007) .
In conclusion, this study shows that Fhit controls the invasive phenotype of lung tumor cells by regulating several EMT key events such as cell-cell adhesion and MMP and vimentin expression. Taken together with our data showing the regulation of the invasiveness of several lung and mammary cell lines by Fhit, these results suggest a general mechanism of control of tumor invasion by Fhit. Thus, this study highlights a dual role for Fhit during cancer progression. Besides its tumor suppressive function, Fhit is also a tumor invasion suppressor gene. This study therefore reinforces the usefulness of Fhit detection as a prognostic marker and of Fhit gene therapy for the treatment of cancer.
Materials and methods

Tumor tissue samples
Surgically resected tumors were collected after obtaining informed consent from 48 patients with primary NSCLC (28 squamous-cell carcinomas and 20 adenocarcinomas) of stages I (15 cases), II (19 cases) and III (14 cases) according to the TNM classification. A total of 26 normal lung tissues matching the tumor samples were also collected.
Tumor cell lines
Human lung HBE4-E6/E7, A549, BEAS-2B, NCI-H1299 and BZR and mammary T47D, MCF-7, BT-20, MDA-MB-231 and Hs578T cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA). BZR-T33 lung cells were provided by Curtis C Harris (National Cancer Institute, Bethesda, MD, USA). A549, BEAS-2B, BZR, BZR-T33, T47D, MCF-7, BT-20, MDA-MB-231 and Hs578T were cultured in DMEM (Gibco, Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum (FCS) (Gibco), and NCI-H1299 in RPMI (Gibco) containing 10% FCS and HBE4-E6/ E7 in Keratinocyte-SFM (Gibco) supplemented with 0.2 ng/ml EGF and 25 mg/ml BPE.
Stable transfection of Fhit expression vector
The eukaryotic expression plasmid pcDNA3.1/Zeo (À)-Fhit expressing the Fhit cDNA was constructed by subcloning the XhoI/HindIII fragment from the pUSEamp(À)-Fhit plasmid (Upstate Biotechnology, Lake Placid, NY, USA) into the pcDNA3.1/Zeo (À) vector (Invitrogen). NCIH-1299 cells were stably transfected with the pcDNA3.1/Zeo (À)-Fhit plasmid or the pcDNA3.1/Zeo (À) empty vector by electroporation. The transfected populations were subjected to a selective pressure with zeocin. (Eurogentec, Seraing, Belgium). Three corresponding scrambled duplexes that do not recognize any sequence in the human genome were used as controls. A total of 100 000 HBE4-E6/E7 cells were transfected with a mix of the three siRNA duplexes (20 nM) by calcium phosphate-precipitation method as previously described . Supernatants and cells cultured for 24 h without BPE were then harvested for zymography, RT-PCR and western blot analyses.
RT-PCR analysis RNA was extracted from normal and tumor lung tissues frozen in liquid nitrogen with the RNA Easy Qiagen kit (Qiagen, MD, USA) and from NCI-H1299 and HBE4-E6/E7 transfectants with the High Pure RNA isolation kit (Roche Diagnostics GmbH, Mannheim, Germany). . RT-PCR was performed by using the Thermostable rTth Reverse Transcriptase RNA PCR kit (Applied Biosystem, Foster City, CA, USA) as previously described .
Immunohistochemistry
Immunohistochemistry for Fhit was carried out on paraffin serial sections. After antigen retrieval pretreatment in citrate buffer, slides were incubated with a rabbit polyclonal antiboby to Fhit (1:200) (ZR44; Zymed, Invitrogen). Subsequent steps were performed with the LSAB þ system-AP kit (Dako, Carpinteria, CA, USA). Alkaline phosphatase activity was revealed with fuschin þ substrate-chromogen (Dako). Slides were counterstained with Mayer's haematoxylin.
Immunofluorescence Subconfluent monolayers of NCI-H1299 and HBE4-E6/E7 transfectants cultured on glass coverslips were fixed with methanol or paraformaldehyde for analysis of adhesion molecules or Fhit, respectively. The coverslips were incubated with a mouse monoclonal antibody against occludin (1:25) (clone OC-3F10, Zymed), a mouse monoclonal antibody against ZO-1 (1:25) (clone ZO1-1A12, Zymed), a mouse monoclonal antibody against E-cadherin (1:100) (clone 36, BD Transduction Laboratories, BD Biosciences, San Jose, CA, USA), a mouse monoclonal antibody against b-catenin (1:500) (clone 14, BD Transduction Laboratories) or a rabbit polyclonal antibody against Fhit (1:25) (ZR44). Monolayers were next incubated with Alexa Fluor 594-coupled anti-mouse or anti-rabbit IgG (1:200) (Molecular Probes, Eugene, OR, USA). Nuclei were stained with Dapi (Molecular Probes).
Western blotting
Total proteins were extracted in radioimmunoprecipitation assay buffer containing a complete protease inhibitor cocktail (Roche Diagnostics GmbH). Proteins were separated on SDS-PAGE gels and transferred to a polyvinylidene difluoride membrane (NEN, Boston, MA, USA). The membranes were incubated with either a rabbit polyclonal antibody to Fhit (1:250) (ZR44) or mouse monoclonal antibodies to MT1-MMP (1:1000) (clone 2D7, provided by Dr Rio, IGBMC, Illkirch, France), vimentin (1:1000) (clone V9, Dako), occludin (1:1000) (clone OC-3F10), ZO-1 (1:1000) (clone ZO1-1A12), E-cadherin (1:2500) (clone 36) and b-catenin (1:5000) (clone 14). The following steps were performed as previously described . Subsequent detection of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (using a mouse antibody, 1:300, clone 6C5, Chemicon, Millipore, Billerica, MA, USA) was performed on the same filters as a control.
2D migration assay
For each cell type, 5 Â 10 4 cells were seeded inside a restriction glass ring. After 48 h, the ring was removed to induce cell migration. After 24 h, cell migration analysis was performed using an inverted microscope (Axiovert 200, Zeiss, Oberkochen, Germany) equipped with an environmental chamber (Incubator XL-3, Pecon, Erbach, Germany) with 5% CO 2 in air at 37 1C and a charge-coupled device camera (Coolsnap, Roper Scientific, Photometrics, Tucson, AZ, USA) and driven by the Axiovision software (Zeiss). Image sequences of the cells were recorded every 15 min for 6 h at Â 20 magnification and the trajectories and the migration speeds were analysed with a software developed in our laboratory (Zahm et al., 1997) .
3D migration assay
A two-layer type-I collagen gel was prepared on Transwell (Corning Incorporated, Corning, NY, USA). A total of 2.5 Â 10 4 cells were incorporated in the second collagen gel layer. Cell migration analysis was performed using the same microscope and camera as for 2D migration assay. Image sequences of the cells within the collagen gel were recorded every hour at 150 successive Z levels (3 mm between each depth level) at Â 10 magnification. The migratory behavior of the cells was finally analysed by using a cell tracking software developed in our laboratory, which allows the 3D representation of the trajectories and the migration speed quantitation in xy and z planes (Hazgui et al., 2005) .
Modified Boyden chamber invasion assay
The in vitro invasive properties of cells were assessed using a modified Boyden chamber assay. A total of 10 5 cells were placed in the upper compartment of the invasion chamber (BD BioCoat Matrigel Invasion Chamber, BD Biosciences, Bedford, MA, USA). For MMP inhibition experiments, the broad-spectrum synthetic MMP inhibitor GM6001 (Calbiochem, Merck Biosciences, Darmstadt, Germany) was added to the cells in the upper compartment of the insert (10-100 mM). The chambers were incubated for 24 h at 37 1C. The filters were then fixed in methanol and stained with haematoxylin. Quantification of the invasion assay was performed by counting the number of cells at the lower surface of the filters (23 fields at 400-fold magnification).
Gelatin zymography analysis Supernatants of cells grown for 48 h in serum-free conditions were collected, centrifugated and separated on 10% polyacrylamide SDS gel containing 0.1% (w/v) gelatin. The gel was washed for 1 h at room temperature in a 2% (v/v) Triton X-100 solution, transferred to a 50 mM Tris-HCl/10 mM CaCl 2 (pH 7.6) buffer and incubated overnight at 37 1C. The gel was stained in a 0.1% (w/v) Coomassie Blue (G250)/45% (v/v) methanol/10% (v/v) acetic acid solution and de-stained in a 10% (v/v) acetic acid/20% (v/v) methanol solution.
MT1-MMP activity assay
Active MT1-MMP level was measured with the MMP-14 Biotrack Activity Assay System according to the manufacturer's instructions (Amersham, GE Healthcare, Buckinghamshire, UK).
Statistical analysis
Data are expressed as means±standard deviation. The nonparametric Mann-Whitney U-test was used for statistical analyses. Po0.05 was considered to be significant.
